SG Americas Securities LLC Has $857,000 Stock Holdings in Vera Therapeutics, Inc. (NASDAQ:VERA)

SG Americas Securities LLC lifted its position in Vera Therapeutics, Inc. (NASDAQ:VERA) by 116.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 20,270 shares of the company’s stock after buying an additional 10,916 shares during the quarter. SG Americas Securities LLC’s holdings in Vera Therapeutics were worth $857,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. increased its position in Vera Therapeutics by 21.4% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company’s stock worth $86,000 after acquiring an additional 350 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Vera Therapeutics in the second quarter valued at about $163,000. AlphaCentric Advisors LLC acquired a new stake in Vera Therapeutics during the third quarter worth about $332,000. China Universal Asset Management Co. Ltd. increased its stake in Vera Therapeutics by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,545 shares of the company’s stock valued at $466,000 after acquiring an additional 4,118 shares during the period. Finally, Intech Investment Management LLC acquired a new position in Vera Therapeutics in the 3rd quarter valued at approximately $475,000. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Stock Performance

Shares of Vera Therapeutics stock opened at $35.98 on Wednesday. Vera Therapeutics, Inc. has a fifty-two week low of $29.33 and a fifty-two week high of $51.61. The firm has a market capitalization of $2.28 billion, a P/E ratio of -13.79 and a beta of 1.15. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. The company’s 50 day moving average price is $42.18 and its two-hundred day moving average price is $40.91.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.21). On average, equities analysts forecast that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Insider Transactions at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 17,500 shares of the company’s stock in a transaction on Wednesday, December 18th. The stock was sold at an average price of $43.07, for a total transaction of $753,725.00. Following the completion of the sale, the chief executive officer now owns 85,942 shares in the company, valued at approximately $3,701,521.94. This represents a 16.92 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Insiders have sold 52,500 shares of company stock valued at $2,305,625 in the last 90 days. 21.70% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

A number of equities analysts have recently commented on VERA shares. Wedbush raised their price objective on shares of Vera Therapeutics from $30.00 to $38.00 and gave the stock a “neutral” rating in a report on Friday, November 8th. The Goldman Sachs Group initiated coverage on Vera Therapeutics in a research report on Tuesday. They issued a “buy” rating and a $58.00 price target on the stock. Wells Fargo & Company started coverage on Vera Therapeutics in a report on Thursday, November 21st. They set an “overweight” rating and a $70.00 price objective for the company. JPMorgan Chase & Co. upped their price objective on shares of Vera Therapeutics from $72.00 to $75.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Finally, Scotiabank assumed coverage on Vera Therapeutics in a research report on Wednesday, October 16th. They set a “sector outperform” rating and a $60.00 price target on the stock. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $67.50.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.